Key result
Sacubitril/valsartan significantly decreased blood pressure, renal tubule fibrosis, glomerular fibrosis, and glomerular injury compared to valsartan alone in a salt-sensitive hypertensive mouse model.
Why the study?
Aldosterone breakthrough during long-term angiotensin blockade is linked to declining GFR via profibrotic actions, prompting investigation into whether sacubitril/valsartan offers additional organ-protective actions beyond angiotensin blockade.
Does sacubitril/valsartan reduce blood pressure and renal fibrosis compared to valsartan in a salt-sensitive hypertensive mouse model?
Does sacubitril/valsartan reduce blood pressure and renal fibrosis compared to valsartan in a salt-sensitive hypertensive mouse model?
Sacubitril/valsartan provides additional blood pressure reduction and renal protection beyond AT1 receptor blockade in a salt-sensitive hypertensive mouse model.
Answers are grounded in this paper and cite their sources.
Does not support clinical use; hypothesis-generating for ARNI renal benefits, requiring human trials.
Introduction: “Aldosterone breakthrough,” which is observed in patients receiving long term treatment with angiotensin blockade, is strongly associated with the increased risk of a declining glomerular filtration rate through the profibrotic actions of aldosterone. Sacubitril/valsartan is a newly created combination medicine (the angiotensin receptor blocker valsartan and the neprilysin-inhibitor sacubitril). Therefore, sacubitril/valsartan should have additional organ-protective actions besides the angiotensin blockade. Methods: In this study, we examined the renal protective effect of sacubitril/valsartan in a salt-sensitive hypertension model using angiotensin II type 1a receptor (AT1aR) knockout mice. An oral administration of 1% NaCl solution with sacubitril/valsartan (30 or 60 mg/kg/day) or valsartan (15 or 30 mg/kg/day) alone beginning 7 days before administration of aldosterone was examined in an aldosterone infusion AT1R knockout mouse model as an aldosterone breakthrough model. Results / Conclusion: A significant decrease in Blood Pressure (BP) was observed in the sacubitril/valsartan group compared to the valsartan group under low and high doses. In addition, the pathological analysis of the kidney for glomerular fibrosis by Sirius red staining and for injury by PAS staining demonstrated significant reductions accompanied by a significant reduction in TGF-β in the sacubitril/valsartan group compared to the valsartan group. Overall, sacubitril/valsartan, which has the dual actions of the AT1R blockade and neprilysin inhibition, may have additional clinical values for the treatment of hypertensive patients with aldosterone breakthrough.
No takes yet. Share an insight, caveat, or question.
Otsu et al. (2018) studied Salt-sensitive hypertension (n=60). Sacubitril/Valsartan vs. Valsartan (15 or 30 mg/kg/day) or no treatment was evaluated on Renal tubule fibrosis, glomerular fibrosis, and glomerular injury (p=<0.01). Sacubitril/valsartan significantly decreased blood pressure, renal tubule fibrosis, glomerular fibrosis, and glomerular injury compared to valsartan alone in a salt-sensitive hypertensive mouse model.
Synapse has enriched 10 related papers. Consider them for comparative context: